Kevin Waweru Mwangi
PhD Student
Ghent University - PROVAXS
GENT, Belgium
I’m a PhD student working on mRNA-based lipid nanoparticle (LNP) vaccines for lung cancer. Focus on harnessing these platforms to immunomodulate the TME.
My organisation
About me
I am a PhD student investigating mRNA-based lipid nanoparticle (LNP) vaccines for lung cancer immunotherapy. My research focuses on using the Galsome platform to deliver mRNA to specific subsets of dendritic cells (DCs), aiming to prime cytotoxic T cells and induce broader immune responses. We are particularly interested in how this targeted activation can also generate bystander effects on unconventional T cell populations. Using the Lewis lung carcinoma (LLC) mouse model, I explore how this approach can reshape the tumor microenvironment and improve anti-tumor efficacy in non-small cell lung cancer.